165 related articles for article (PubMed ID: 8057112)
1. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.
Planté-Bordeneuve V; Davis MB; Maraganore DM; Marsden CD; Harding AE
J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):911-3. PubMed ID: 8057112
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
[TBL] [Abstract][Full Text] [Related]
3. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
[TBL] [Abstract][Full Text] [Related]
4. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
Landi MT; Ceroni M; Martignoni E; Bertazzi PA; Caporaso NE; Nappi G
Adv Neurol; 1996; 69():61-72. PubMed ID: 8615186
[No Abstract] [Full Text] [Related]
5. Mutant debrisoquine hydroxylation genes in Parkinson's disease.
Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR
Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052
[TBL] [Abstract][Full Text] [Related]
6. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
Bordet R; Broly F; Destée A; Libersa C
Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
[No Abstract] [Full Text] [Related]
7. Association between the oxidative polymorphism and early onset of Parkinson's disease.
Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 allelic frequencies in young-onset Parkinson's disease.
Sandy MS; Armstrong M; Tanner CM; Daly AK; Di Monte DA; Langston JW; Idle JR
Neurology; 1996 Jul; 47(1):225-30. PubMed ID: 8710083
[TBL] [Abstract][Full Text] [Related]
9. Familial Parkinson's disease and polymorphism at the CYP2D6 locus.
Mazzetti P; Le Guern E; Bonnet AM; Vidailhet M; Brice A; Agid Y
J Neurol Neurosurg Psychiatry; 1994 Jul; 57(7):871-2. PubMed ID: 8021689
[No Abstract] [Full Text] [Related]
10. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis.
Siddons MA; Pickering-Brown SM; Mann DM; Owen F; Cooper PN
Neurosci Lett; 1996 Apr; 208(1):65-8. PubMed ID: 8731176
[TBL] [Abstract][Full Text] [Related]
11. Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13?
Wilhelmsen K; Mirel D; Marder K; Bernstein M; Naini A; Leal SM; Cote LJ; Tang MX; Freyer G; Graziano J; Mayeux R
Ann Neurol; 1997 Jun; 41(6):813-7. PubMed ID: 9189044
[TBL] [Abstract][Full Text] [Related]
12. A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease.
Tsuneoka Y; Matsuo Y; Iwahashi K; Takeuchi H; Ichikawa Y
J Biochem; 1993 Aug; 114(2):263-6. PubMed ID: 7903297
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine hydroxylase gene polymorphism in meningioma.
Wundrack I; Meese E; Müllenbach R; Blin N
Acta Neuropathol; 1994; 88(5):472-4. PubMed ID: 7847077
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquine hydroxylase and Parkinson's disease.
Kondo I; Kanazawa I
Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
[TBL] [Abstract][Full Text] [Related]
15. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
Hadidi HF; Cholerton S; Monkman SC; Armstrong M; Irshaid YM; Rawashdeh NM; Daly AK; Idle JR
Pharmacogenetics; 1994 Jun; 4(3):159-61. PubMed ID: 7920696
[No Abstract] [Full Text] [Related]
16. CYP2D6 polymorphism and Parkinson's disease susceptibility.
Sabbagh N; Brice A; Marez D; Dürr A; Legrand M; Lo Guidice JM; Destée A; Agid Y; Broly F
Mov Disord; 1999 Mar; 14(2):230-6. PubMed ID: 10091614
[TBL] [Abstract][Full Text] [Related]
17. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.
Kurth MC; Kurth JH
Am J Med Genet; 1993 Oct; 48(3):166-8. PubMed ID: 8291573
[TBL] [Abstract][Full Text] [Related]
18. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism.
Kösel S; Lücking CB; Egensperger R; Mehraein P; Graeber MB
J Neurosci Res; 1996 Apr; 44(2):174-83. PubMed ID: 8723226
[TBL] [Abstract][Full Text] [Related]
20. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease.
Tsuneoka Y; Matsuo Y; Ichikawa Y; Watanabe Y
Metabolism; 1998 Jan; 47(1):94-6. PubMed ID: 9440484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
